These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28281842)

  • 1. Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?
    Bhattacharya P; Abderrahman B; Jordan VC
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):297-310. PubMed ID: 28281842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
    Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
    Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
    Van Asten K; Poppe A; Punie K; Jongen L; Lintermans A; Wildiers H; Neven P
    Curr Treat Options Oncol; 2015 Jul; 16(7):31. PubMed ID: 26031545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
    Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
    Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended adjuvant endocrine therapy - A standard to all or some?
    Ribnikar D; Sousa B; Cufer T; Cardoso F
    Breast; 2017 Apr; 32():112-118. PubMed ID: 28152498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.
    Jordan VC
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25269699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
    Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
    J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
    Smith IE; Yeo B; Schiavon G
    Am Soc Clin Oncol Educ Book; 2014; ():e16-24. PubMed ID: 24857098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
    Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
    Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
    Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant aromatase inhibitor therapy in patients with stage I breast cancer at a regional oncology center in Israel: implementation of a 'switching' policy in postmenopausal patients after initial tamoxifen.
    Geffen DB; Tokar M; Abu-Ghanem S; Braunstein R; Koretz M; Amir N; Delgado B; Sion-Vardi N; Ariad S; Lazarev I
    Oncology; 2013; 85(3):145-52. PubMed ID: 23988814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence rates and correlates in long-term hormonal therapy.
    Dunn J; Gotay C
    Vitam Horm; 2013; 93():353-75. PubMed ID: 23810015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.